2018 AANS Annual Scientific Meeting-Meningioma Surgery

Video Transcription

Video Summary

In this video, Dr. Melling from Norway discusses the progress made in meningioma surgery. He begins by defining progress and the different endpoints used to measure it, such as overall survival, re-treatment-free survival, and complications. Dr. Melling explains that effectiveness studies, including randomized controlled trials and observational studies, are commonly used to study progress. He presents data on 30-day mortality rate and resection grade, showing a decrease in mortality rate over time and a slight increase in resection grade. He then presents findings from his own study using a meningioma database, showing that patients in more recent years are older and more asymptomatic, and that there have been improvements in gross total resection, mortality, and retreatment-free survival. Dr. Melling suggests that subspecialization, particularly in skull base surgery, may be a primary driver of these improvements. He also acknowledges the limitations of his study, such as not having data on radiation treatment. The video concludes with a question from Dr. Al Mefti about the impact of radiation treatment on meningiomas, which Dr. Melling admits he doesn't have data on. Overall, the video highlights the progress and improvements seen in meningioma surgery, attributing some of the success to subspecialization.

Asset Caption

Torstein R. Meling, MD, PhD, IFAANS (Norway)

Keywords

meningioma surgery

progress

overall survival

re-treatment-free survival

complications